Ask an injector what happens if a filler patient loses vision and you will usually get a version of the same answer: there is a procedure for that. Retrobulbar hyaluronidase. You go behind the eye, you dissolve the product, you have a window.
That belief is doing real work in aesthetic practice. It is the reason some injectors treat the glabella and the nasal dorsum with less caution than the anatomy warrants, because the worst outcome feels retrievable. It functions as a safety net.
It is not one, and this article sets out why — not as an opinion, but as a chain of individually cited findings that ends in a different plan.
Melissa Pulcini-Buttine, PA, describes the procedure to students in a way that gets the emphasis right even when the details compress: "The only way to get into that retinal artery, you have to be very skilled with anatomy… you have to go behind the eyeball. It's a very complicated procedure." Her instruction that follows is the part to keep: "Have your protocols ready."
The question is what the protocol should actually say.
Where this technique came from
The technique entered aesthetic medicine in a 2015 paper by three highly experienced authors, and the paper's own framing is the first thing that should give an injector pause.
Its stated goal was to "demonstrate a technique of retro or peribulbar injection of hyaluronidase should such an emergency arise if no ophthalmologist was immediately available." And then, in the same abstract: "None of us have yet used this technique to treat iatrogenic filler induced blindness, but we present the information for the benefit of patient safety" (Carruthers J, Fagien S, Dolman P. Retro or PeriBulbar Injection Techniques to Reverse Visual Loss After Filler Injections. Dermatol Surg. 2015;41 Suppl 1:S354-S357. PMID 26618464).
That is an honest and responsible paper. It is also not what it has become. A contingency published by authors who had never performed it on a filler-blindness patient, explicitly framed as a fallback when ophthalmology is unavailable, has been absorbed into the field as a standard rescue that injectors believe they possess.
What the outcome data show
Two independent systematic reviews have examined the question directly.
The first found only five anecdotal descriptions in the entire literature, covering nine patients, of whom two improved. Its conclusion is unambiguous: "To date, there have been no case-control, cohort, or randomized control studies to evaluate this treatment… There is not currently enough evidence to support retrobulbar hyaluronidase as a treatment for filler-induced blindness" (Paap MK, Milman T, Ugradar S, Goldberg R, Silkiss RZ. Examining the Role of Retrobulbar Hyaluronidase in Reversing Filler-Induced Blindness: A Systematic Review. Ophthalmic Plast Reconstr Surg. 2020;36(3):231-238. PMID 31880685).
A second, independent systematic review identified 17 treated patients with improvement in three, concluding: "There is no confirmed evidence of retrobulbar hyaluronidase injection effectiveness" (Navarro-Hernandez E, Pérez-López M. Arch Soc Esp Oftalmol. 2022;97(9):521-538. PMID 35787383).
The standing review of the world literature on filler blindness now covers 511 cumulative published cases. Of the 318 with reported visual outcomes, 6.0% recovered completely, 25.8% partially and 68.2% not at all — and the authors state plainly that "no treatments were significantly associated with visual improvement (P > .05)." Within that series, retrobulbar hyaluronidase was attempted in 38 cases and improved vision in two, a 5.3% success rate. The strongest predictor of recovery was not any intervention but partially preserved acuity at onset — that is, the patients who did better were the ones who were less completely occluded to begin with (Doyon VC, Liu C, Fitzgerald R, et al. Update on Blindness From Filler. Aesthet Surg J. 2024;44(10):1091-1104. PMID 38630871).
The American Academy of Ophthalmology has now issued a formal Ophthalmic Technology Assessment on the subject. Reviewing 198 cases across 19 articles — all of them rated level III evidence — it reports 70% unchanged, 28% improved and 2% worsened, and concludes that these interventions "although safe, were usually not effective in reversing vision loss" and that "no evidence-based protocol has been established for managing vision loss" (Foster J, Aakalu VK, Freitag SK, et al. Ophthalmology. 2025;132(8):935-944. PMID 40167411).
The counterexample deserves naming, because pretending it does not exist would be the same error in the opposite direction. A 38-year-old woman who lost all perception of light after 0.15 mL of hyaluronic acid to the nasal tip, with a documented central retinal artery occlusion and a cherry-red spot, received 675 IU immediately and then 3,000 IU intra-orbitally plus 1,500 IU extra-orbitally within four hours. She recovered to 6/18 the next day and 6/6 at one month (Danks JJ, Dalgliesh JD, Ayton T. Cosmetic Filler Blindness: Recovery After Repeated Hyaluronidase Injections. Aesthet Surg J. 2022;42(4):411-416. PMID 34480547). That happened at a tertiary referral eye hospital.
So the honest position is not "it never works." It is that a pooled success rate around 5%, in a literature with no controlled studies and universally level III evidence, does not constitute a rescue plan.
Why it probably cannot work: the enzyme does not reach the target
The outcome data would be easier to dismiss as a timing problem were it not for the laboratory work, which supplies a mechanism for the failure.
Two independent groups, publishing in the same journal in the same year, asked whether hyaluronidase can physically reach filler inside the central retinal artery, which runs within the dural sheath of the optic nerve.
The first injected human cadaveric optic nerves with hyaluronic acid gel and then either injected hyaluronidase directly into the nerve — which produced partial digestion, proving the enzyme works when it arrives — or immersed the nerve in undiluted hyaluronidase to simulate a retrobulbar injection. The result: "Immersion in undiluted hyaluronidase led to no apparent gross or microscopic digestion… Hyaluronidase does not demonstrate the ability to cross the dural sheath of the optic nerve, suggesting that retrobulbar hyaluronidase injection is unlikely to alleviate hyaluronic acid gel-mediated central retinal artery occlusion and blindness" (Paap MK, Milman T, Ugradar S, Silkiss RZ. Plast Reconstr Surg. 2019;144(2):315-320. PMID 31348334).
The second group ligated fresh optic nerve segments watertight after injecting highly cross-linked hyaluronic acid, then immersed them in 1,500 IU/mL hyaluronidase for twenty-four hours. "After 24 hours, there was a persistence of hyaluronic acid within the optic nerves. There is a lack of evidence for penetration of optic nerve sheath by hyaluronidase" (Adulkar N, Cheng C, Lee L, Rasmussen S, Dolman PJ, Yin VT. Plast Reconstr Surg. 2019;144(1):43e-47e. PMID 31246809).
Twenty-four hours of immersion in concentrated enzyme, and it still did not get through. The clinical window is measured in minutes.
The animal work is genuinely conflicting, and the nature of the conflict is instructive rather than reassuring. A rabbit model delivering 1,000 IU retrobulbar at 30 minutes after occlusion found no improvement in perfusion and flat electroretinograms at 120 minutes (Hwang CJ, Mustak H, Gupta AA, et al. Ophthalmic Plast Reconstr Surg. 2019;35(1):33-37. PMID 29877958). A second rabbit model delivering 3,000 IU at five and ten minutes found improved reperfusion in three of four completely occluded eyes (Lee W, Oh W, Ko HS, et al. Plast Reconstr Surg. 2019;144(1):137-143. PMID 31246817).
The difference is a threefold dose and a delivery time of five to ten minutes. That is the strongest available case for the procedure — and it is simultaneously the clearest demonstration that it is not deliverable in an aesthetic clinic. Nobody recognises visual loss, confirms the diagnosis, reconstitutes 3,000 IU, positions a frightened patient and places a needle into an orbit within ten minutes.
The clock is worse than you were told
Injectors have generally absorbed a figure of roughly 90 minutes as the retinal tolerance window. It has a real source: primate work found that the retina "suffered irreparable damage after ischaemia of 105 minutes but recovered well after ischaemia of 97-98 minutes" (Hayreh SS, Weingeist TA. Br J Ophthalmol. 1980;64(11):818-825. PMID 7426553), a finding the same investigator later summarised as no detectable permanent damage at 97 minutes with irreversible damage by four hours (Hayreh SS. Prog Retin Eye Res. 2011;30(5):359-394. PMID 21620994).
That figure is now directly contested, and any injector relying on it should know that. A 2018 analysis argues the experimental basis for the 90-to-240-minute interval "is flawed in important ways," notes that retinal ganglion cells are central nervous system tissue that infarcts after 12 to 15 minutes of non-perfusion, and concludes: "Retinal infarction is most likely to occur after only 12-15 min of complete CRAO. This helps to explain why therapeutic maneuvers for CRAO are often ineffective" (Tobalem S, Schutz JS, Chronopoulos A. BMC Ophthalmol. 2018;18(1):101. PMID 29669523).
Take either figure. At 90 minutes, a rescue requiring recognition, drug preparation and an orbital injection is barely conceivable. At 12 to 15 minutes for a complete occlusion, it is not deliverable by anyone, anywhere, including an ophthalmologist who is not already standing in the room.
What the procedure actually demands
This article does not describe how to perform a retrobulbar injection, and deliberately so. What follows is what the procedure requires, so that a clinician can assess honestly whether they are equipped to do it.
A published anatomical practice guideline based on cadaveric dissection and micro-CT describes a 35 mm, 22-to-23-gauge needle, an inferolateral orbital approach chosen specifically because it is the safest available trajectory, and doses of 1,500 to 3,000 IU. It names the risks as globe perforation — particularly with a medial approach — optic nerve injury, and damage to extraocular muscles and vascular structures, and concludes that "clinical implementation should proceed with caution and in multidisciplinary settings" (Yi KH, Kim JH, Lee HE, Song JK, Cho B, Kim SB. Anatomical Guideline for Retrobulbar Hyaluronidase Injection. J Cosmet Dermatol. 2025;24(8):e70378. PMID 40762195).
A companion paper from the same group argues that real-time ultrasound is required for precision, noting that the superior orbital rim and the proximity of the globe restrict needle trajectory and increase the risk of ocular injury (Yi KH, Kim SB, Hu H, Thulesen J, Wan J, Kim HJ. Anat Cell Biol. 2025;58(4):504-510. PMID 41125554). Read that carefully: the current best-practice description of this technique involves orbital ultrasound guidance, which is not equipment an aesthetic clinic has, operated by a skill an aesthetic injector does not possess.
A review of efficacy and technique published in 2019 is rated by its own journal as Level of Evidence V — expert opinion — and concedes that "positive outcomes remain anecdotal" (Surek CC, Said SA, Perry JD, Zins JE. Aesthetic Plast Surg. 2019;43(4):1034-1040. PMID 31065750).
The complication you would be creating
The risk of the procedure is not theoretical, and it is quantified — in a population and setting far more favourable than an aesthetic emergency.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Aesthetic & Injectable Training courses — live patients, expert faculty, and ongoing mentorship.
A prospective multicentre study of 16,224 consecutive peribulbar blocks — peribulbar being the shallower, safer variant — reported orbital haemorrhage in 0.74%, globe perforation in 0.006% and expulsive haemorrhage in 0.013% (Davis DB, Mandel MR. J Cataract Refract Surg. 1994;20(3):327-337. PMID 8064611). Those blocks were performed by ophthalmologists, anaesthesiologists and nurse anaesthetists, using a needle of 1¼ inches or shorter, on calm, scheduled, prepared cataract patients.
Roughly one in 135 produced an orbital haemorrhage under those conditions. Retrobulbar is deeper and carries higher risk than peribulbar.
And an orbital haemorrhage is itself a cause of blindness. A systematic review of 93 retrobulbar haematoma cases found that 22% developed blindness, with 51% achieving complete recovery and 27% partial (Christie B, Block L, Ma Y, Wick A, Afifi A. J Plast Reconstr Aesthet Surg. 2018;71(2):155-161. PMID 29239798).
There is one further data point worth absorbing. In a UK national survey of roughly 357,000 local-anaesthetic cataract procedures, only 1.3% used a retrobulbar block (Lee RM, Thompson JR, Eke T. Br J Ophthalmol. 2016;100(6):772-776. PMID 26405103). Ophthalmology has very largely abandoned this approach in its own hands, on safety grounds, in elective conditions.
The proposal, then, is that an aesthetic injector perform in an unplanned emergency, on a panicking patient, without ultrasound, without an orbital surgeon's training, a procedure that ophthalmologists have mostly stopped performing on calm patients in an operating suite — where the complication rate is roughly one in 135 and the complication blinds one patient in five.
What the consensus bodies actually tell an injector to do
This is the part that should replace the belief.
A consensus specifically examining the scope question concluded: "The current evidence base does not support the use of retrobulbar and peribulbar hyaluronidase. Its efficacy remains unproven and there is mixed evidence within the literature. The current evidence suggests that there may be an increased risk of introducing severe adverse events associated with retrobulbar hyaluronidase and may even exacerbate the problem for those clinicians who are not ophthalmology trained. Therefore, we recommend two alternative treatment pathways for ophthalmology and non-ophthalmology trained practitioners" (Walker L, Convery C, Davies E, Murray G, Croasdell B. Consensus Opinion for The Management of Soft Tissue Filler Induced Vision Loss. J Clin Aesthet Dermatol. 2021;14(12):E84-E94. PMID 35096260).
The non-ophthalmology pathway in that document contains no orbital injection. It is: stop treatment immediately; arrange immediate transfer by ambulance or drive the patient with the clinician accompanying; test and document visual acuity by counting fingers, hand motions or light perception; aspirin 300 mg; timolol 0.5%; ocular massage; paper-bag rebreathing. The retrobulbar option appears only in the ophthalmology-trained pathway.
A separate 22-author consensus statement gives compatible guidance: seek help from in-clinic colleagues and "aim to transfer the patient at the earliest opportunity to external personnel such as an emergency physician from a specialist eye hospital"; document the time of onset; assess acuity, pupils and eye movements with a brief neurological screen. On the orbital injection: it "should only be performed if the operator has expertise in this injection technique and feels confident in the diagnosis," and critically, "any treatment should not delay appropriate transfer." The same panel recommends against attempting aspiration and against bedside anticoagulation (Goodman GJ, Magnusson MR, Callan P, et al. Aesthet Surg J. 2020;40(9):1009-1021. PMID 31693068).
An earlier expert-group guideline states that retrobulbar injection "should only be considered by practitioners competent in this procedure in a specialist eye unit" (Walker L, King M. J Clin Aesthet Dermatol. 2018;11(5):E53-E55).
Even the ophthalmology-side view, which is more favourable to the procedure, is conditioned the same way: it remains contentious, but "when administered by a specialist, this treatment gives the best chance at visual recovery" (Botha VE, Insull EA. Clin Exp Ophthalmol. 2024;52(3):365-373. PMID 38380782).
To be accurate about what does not exist: no professional society has issued a formal scope-of-practice prohibition on non-ophthalmologists performing this injection. The closest thing is the two-pathway consensus above, which was written precisely to keep non-ophthalmologists out of the orbit.
The plan that should replace it
Melissa's instruction — "have your protocols ready" — is right. The protocol just should not contain a retrobulbar needle.
Identify the receiving service before the day you need it. Not "an eye hospital." A named ophthalmology service or emergency department, with a phone number, a travel time and a route, written down and posted. The single most consequential variable in every one of these case series is time to definitive care, and the minutes are lost during the search, not the drive.
Decide who drives and who calls. The clinician accompanies the patient. Someone else calls ahead so the receiving team is expecting a filler-associated central retinal artery occlusion rather than working it out on arrival.
Document onset time and acuity before you leave. Counting fingers, hand motions, light perception. This is a ninety-second assessment that materially changes what the receiving team can do, and it is the one thing an injector is unambiguously qualified to contribute.
Know that the non-invasive measures in the consensus pathways are adjuncts, not treatment, and that none of them may delay transfer.
Brief your non-injecting staff, because the recognition step usually happens on the phone rather than in the chair. That is a separate and genuinely under-built system in most practices.
And accept where the real lever is. Every one of the papers above describes attempts to reverse an event after it has occurred, and every one of them reports that reversal mostly fails. The intervention with a demonstrated effect on this outcome is the one that happens before the injection: anatomical knowledge, low pressure, small volumes, and a willingness to stop. "Respect anatomy," as Melissa puts it. "Knowledge is power."
The rescue plan most injectors believe they have is not available to them. The prevention plan is.
The teaching framing in this article reflects Melissa Pulcini-Buttine's clinical practice as taught in Empire Medical Training's hands-on curriculum. This article is educational, describes what a procedure requires rather than how to perform it, and is not a substitute for training.
Clinicians who want to build the prevention side properly should look at Empire's anatomical based aesthetics training and special anatomical cadaver aesthetics training, with regional technique in complete dermal filler training and the highest-risk territories in master eye and nose injection training. Related reading: filler dissolve and can Botox cause blindness.
Melissa Pulcini-Buttine, PA — physician assistant of two decades; professor of anatomy and physiology for ~14 years; faculty member, Empire Medical Training; founder of an aesthetics practice in Greenwich, Connecticut.
Frequently Asked Questions
Does retrobulbar hyaluronidase reverse filler-induced blindness?
Rarely. Two systematic reviews found improvement in 2 of 9 and 3 of 17 treated patients. In the largest cumulative series, it was attempted in 38 cases and improved vision in two, and no treatment was significantly associated with visual improvement. The American Academy of Ophthalmology's assessment found these interventions "usually not effective," on uniformly level III evidence.
Why might retrobulbar hyaluronidase fail mechanistically?
Because the enzyme appears unable to reach the filler. Two independent studies found that hyaluronidase does not cross the dural sheath of the optic nerve, within which the central retinal artery runs. In one, optic nerve segments injected with hyaluronic acid and immersed in 1,500 IU/mL hyaluronidase for 24 hours still contained persistent filler.
How long is the window before retinal damage becomes permanent?
The widely cited figure of roughly 90 minutes comes from primate work showing recovery at 97-98 minutes and irreparable damage at 105. That basis is contested: a 2018 analysis argues retinal ganglion cells are CNS tissue and that infarction most likely occurs after only 12-15 minutes of complete occlusion, which would help explain why rescue manoeuvres so often fail.
Should a non-ophthalmologist injector perform a retrobulbar injection?
Consensus guidance says no. One consensus wrote two separate pathways specifically because retrobulbar hyaluronidase "may even exacerbate the problem for those clinicians who are not ophthalmology trained"; the non-ophthalmology pathway contains no orbital injection. Another states any treatment must not delay transfer. No society has issued a formal prohibition, but the guidance is consistent.
What should an injector actually do if a patient loses vision?
Stop immediately, and arrange immediate transfer to a named ophthalmology service or emergency department identified in advance, with the clinician accompanying the patient. Document time of onset and visual acuity by counting fingers, hand motions or light perception. Call ahead so the receiving team knows what is arriving. Nothing may delay transfer.
Disclaimer
This article reflects the clinical opinions and experience of Melissa Pulcini-Buttine, PA, an independent faculty member contributing to Empire Medical Training's curriculum. The views expressed are the author's own and do not necessarily represent those of Empire Medical Training.
It is professional education, not medical advice, and is no substitute for hands-on training or independent clinical judgment. Licensed clinicians remain responsible for their own patient selection, technique and outcomes, for verifying current product labelling, and for practising within their scope and applicable law. Empire Medical Training accepts no liability for reliance on this content.
